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Abstract:
Duchenne Muscular Dystrophy, the most common inherited X-linked genetic
disease affecting 1 in 5000 boys, results from a dysfunctional dystrophin protein
encoded by the DMD gene. Dystrophin interacts with protein complexes linking the
extracellular matrix to the cytoskeleton of muscle fibers. Without dystrophin functioning
properly, sarcolemmal membrane stabilization is compromised during the mechanical
rigors involved with muscle contraction leading to progressive muscular dystrophy.
Heregulin/neuregulin-1 (HRG), a member of the epidermal growth factor family has
been shown to induce neuromuscular junction (NMJ) gene expression in vitro and
improve skeletal muscle function in dystrophic mice. However, it is unclear if the HRG
effects were due to proliferation, cell survival, differentiation, or stimulation of NMJ
formation to improve excitation-contractile coupling. To identify a mechanism of action,
HRG effects were investigated through in vitro and in vivo experiments: characterization
of downstream signaling, observation of the effects on acetylcholine receptor clustering
in vitro, and observation of NMJ morphology in vivo. In this study we show through
Western blots and electrochemiluminesence assays that AKT and ERK were activated by
HRG, but downstream effects were not clear. HRG decreased laminin-induced AChR
clusters in a dose dependent manner in vitro, resulting in the possible reorganization of
AChRs. In vivo, HRG was found to partially restore NMJ formation and increase axonal
and muscle integration in the NMJ. This study provides evidence that a mechanism of
action for the positive effects of HRG on the dystrophic phenotype in mdx mice are due
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to a reorganization of AChRs and an improvement in NMJ formation, potentially
improving excitation contraction coupling.
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Introduction:
Duchenne muscular dystrophy
Duchenne Muscular Dystrophy (DMD) was first described in 1861 by Edward
Meryon followed by documentation in more detail by Guillaume-Benjamin-Amand
Duchenne in 1868 (Emery & Emery, 1993). Duchenne reported a boy with calf muscle
hypertrophy and evidence of a muscle disease though a histological examination of his
muscle, which is known today as a muscle biopsy (Emery & Emery, 1993; Parent, 2005).
The genetics of DMD were characterized in the 1980’s leading to the discovery that
patients with DMD have an absence or dysfunction of the protein dystrophin in 1987
(Davies et al., 1983; Hoffman, Brown, & Kunkel, 1987).
DMD, the most common muscular dystrophy and X-linked genetic disorder
affecting 1 in 5000 boys, belongs in a class of non-congenital early childhood-onset
muscular dystrophies, with Becker muscular dystrophy being a milder version of
Duchenne seen later in childhood to adulthood (Mendell & Lloyd-Puryear, 2013;
Mercuri & Muntoni, 2013). Usually by the age of 2-3, but sometimes as late as 5 or 6
years, patients with DMD will show symptoms of muscle weakness such as walking on
toes, calf hypertrophy with a slow or awkward gait, exhibit fatigue, have trouble getting
up from a sitting or lying position, and have frequent falls (Cyrulnik, Fee, De Vivo,
Goldstein, & Hinton, 2007; Khurana & Davies, 2003; Sharma, Mynhier, & Miller, 1995).
As a result of the progressive muscle weakness associated with the disease, children are
usually late to walk and will use the Gowers’ maneuver to rise up off the floor, which is a
common warning sign for parents and physicians (Bushby et al., 2010). DMD burdens
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patients while performing daily tasks such as playing with other children and climbing
stairs due to progressive muscle weakness (Khurana & Davies, 2003). Eventually, muscle
weakness is so severe that children around age 10 become permanently wheelchairbound (Voisin & de la Porte, 2004). About 30% of DMD patients have mental retardation
and associated comorbidities such as autism and ADHD (Cyrulnik et al., 2008; Pane et
al., 2012). Death usually occurs from cardiac or pulmonary failure in a patient’s second
or third decades of life (Finder et al., 2004).
DMD pathology is characterized by a repetitive cycle of muscle damage followed
by muscle regeneration and tissue inflammation resulting in progressive muscle loss and
the replacement of healthy tissue with fibro-fatty tissue (Figure 1 and 3) (Archer, Vargas,
& Anderson, 2006; Khurana & Davies, 2003; Voisin & de la Porte, 2004). DMD patients
experience a progressive loss of muscle mass and function in lower leg muscle (Cros,
Harnden, Pellissier, & Serratrice, 1989). Hypertrophy is one of many dramatic
phenotypes seen in early childhood and is characterized in DMD patients by the gain of
mass in calf muscles due to the replacement of muscle with fibro-fatty tissue (Khurana
& Davies, 2003; Verma, Anziska, & Cracco, 2010). Although symptoms can be treated to
some extent and research has progressed over the past few decades, there is no cure.
The most common treatment option is glucocorticoids, which can prolong ambulation
but have consequential side effects such as obesity, short stature, cataracts and
withdrawal (Manzur, Kuntzer, Pike, & Swan, 2004; Schara, Mortier, & Mortier, 2001).
Glucocorticoids only slow the progression of the disease while slightly enhancing
strength by reducing inflammation through immunosuppression (Finder et al., 2004;
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Joshi & Rajeshwari, 2009; Verma et al., 2010). Overall, DMD is an X-linked genetic
disorder resulting in progressive muscle degeneration, cardiac dysfunction, respiratory
deficiency, and early mortality.

Figure 1: Pathophysiology of muscular dystrophy
Adapted from Archer et al., 2006.
Dystrophin
Dystrophin, a 427-kDa protein, is encoded by the largest gene in the human
genome (DMD) at 2.5Mb of genomic sequence that can code for 79 exons (J. M. Tinsley,
Blake, Zuellig, & Davies, 1994; Wells, 2008). Dystrophin has an important structural role
linking the dystrophin-associated glycoprotein complex at its C-terminus to F-actin at its
N-terminus and maintaining sarcolemmal integrity. (Ferlini, Neri, & Gualandi, 2013;
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Nowak & Davies, 2004). An example of the dystrophin-associated glycoprotein complex
and associated proteins is shown below in Figure 2. A key feature of dystrophin that sets
it apart from its homolog, utrophin, is the interaction with neuronal nitric oxide
synthase (nNOS) at its C-terminus. In the absence of functional dystrophin, nNOS is
located in the cytosol rather than near the sarcolemma and is unable to properly
function during a muscle contraction resulting in insufficient blood supply, or ischemia,
which can cause cell necrosis in skeletal and cardiac muscle cells (Heydemann &
McNally, 2004; Sander et al., 2000). The dystrophin protein is also essential for
neuromuscular junction (NMJ) architecture and folding of post-synaptic membranes,
which contain acetylcholine receptors (AChR) (Shiao et al., 2004).
DMD results from mutations in the dystrophin gene (DMD) located on the X
chromosome (Xp21); mutations in the DMD gene are responsible for the missing or
defective dystrophin protein (Davies et al., 1983; Ferlini et al., 2013; Saito et al., 1993;
Tayeb, 2010). Large deletions in the DMD gene occur in 60% of DMD patients (Voisin &
de la Porte, 2004). Point mutations, which usually introduce a premature stop codon,
small deletions and duplications represent the other DMD mutations (Voisin & de la
Porte, 2004). It is estimated that mothers who are carriers of DMD mutations are
responsible for approximately two thirds of patients while the other patients are from
spontaneous germline mutations in the DMD gene (Roberts, 1995).
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Figure 2: Dystrophin-associated glycoprotein complex
Dystrophin provides a crucial mechanical link between the extracellular matrix and
intracellular cytoskeleton. (Davies & Nowak, 2006)

DMD pathology
When dystrophin is absent or truncated, a DMD patient’s muscles deteriorate
and weaken (Wells, 2008). Muscle contraction can cause the weakened sarcolemma to
become increasingly prone to rupture, leading to increased membrane permeability to
Ca2+ (B J Petrof, 1993; Mallouk, Jacquemond, & Allard, 2000; Pato, Davis, Doughty,
Bryant, & Gruenstein, 1983; Turner, Westwood, Regen, & Steinhardt, 1988). The
elevated Ca2+ levels are speculated to contribute to an increased activation of Ca 2+dependent proteases that could affect cell function/viability and early deterioration of
essential proteins in the dystrophin-associated glycoprotein complex (Imbert, Cognard,
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Duport, Guillou, & Raymond, 1995; Ohlendiec, 2002). In addition, altered calcium levels
affect Ca2+-gated K⁺-channels, membrane potential and activation potential for muscle
contraction (Turner et al., 1988). Compromised sarcolemma initiates muscle repair, as
the plasma membrane is a vital barrier and essential for cell survival (Han, Rader, Levy,
Bansal, & Campbell, 2011; Head, 1993; Mallouk et al., 2000). During muscle injury
mitochondria migrate to the area of injury and block off damaged tissue, while muscle
stem cells (satellite cells) proliferate at the site, fuse to form new tubes, fuse with
damaged muscle fibers and restore muscle fiber integrity (Wallace & McNally, 2009). In
patients with DMD, damaged muscle attempts to compensate for tissue injury with help
from satellite cell proliferation, myoblast differentiation and repair; yet, endeavors at
repair are met with partial success and inflammation from macrophage infiltration and
fibrosis are often a result of tissue damage (Nowak & Davies, 2004). Due to the
excessive regeneration of skeletal muscle in patients with DMD, satellite stem cell
populations quickly become depleted preventing muscle repair and results in dystrophic
muscle (Jejurikar & Kuzon, 2003). An example of DMD muscle pathology is shown in
Figure 3.
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Figure 3: DMD muscle pathology
H&E staining of normal (A) and DMD (B-F) muscle tissue showing the consequences due
to the absence of dystrophin resulting in: inflammation (B), degeneration (C), necrosis
(D), regeneration (E), and fibrosis (F) (BioMarin internal figure, courtesy of Sean Bell).
Dystrophin-deficiency is also responsible for NMJ fragmentation on regenerating
muscle fibers (Kong & Anderson, 1999). Since dystrophin is required for AChR
organization, the absence of dystrophin contributes to the reduction and distribution of
AChR clustering over time (Personius & Sawyer, 2005). Nerve-dependent mechanisms
are also responsible for the spatial organization of AChRs (Marques, Pertille, Carvalho, &
Santo Neto, 2007) .
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DMD is lethal. DMD patients are caught in a vicious cycle of progressive muscle
damage and tissue repair. Muscle stem cells can only compensate for so long due to
extensive depletion before necrosis occurs initiating a fatty, fibrous-like, tissue
replacement. Regardless of improvements in medical technology and prolongation of
survival of DMD patients within in the past decades, DMD invariably results in death
usually by cardiac or respiratory failure (Passamano et al., 2012).

mdx, a mouse DMD model
To better understand DMD disease pathology, animal models of dystrophindeficiency are used, such as the mdx mouse (Bulfield, Siller, Wight, & Moore, 1984;
Ryder-Cook et al., 1988). The mdx mouse carries a premature stop codon at exon 23
preventing the production of a functional dystrophin protein (Im et al., 1996). Mdx mice
have a slightly shorter lifespan, reduced cardiac function, and a progressive loss and/or
damage to skeletal muscle (Nowak & Davies, 2004). The disease phenotype in mdx mice
is much less severe when compared to humans. Mdx mice show less fibrosis, a near
normal lifespan and are completely mobile when compared to boys with DMD
(Chamberlain, Metzger, Reyes, Townsend, & Faulkner, 2007). It is believed the mild mdx
phenotype is due to increased compensatory utrophin expression and higher muscle
regeneration capacity in mice (Chamberlain et al., 2007; Pons, Robert, Marini, & Leger,
1994; Weir, Morgan, & Davies, 2004).
As evidence of the effect of the higher regeneration capacity of mice compared
to boys, a dystrophin deficient mouse strain with fewer satellite cells or with reduced
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proliferative capacity was generated. Dystrophin- and telomerase-deficient mice were
generated and shown to have significantly impaired proliferation potential of muscle
satellite cells, and a more sever dystrophic phenotype representative of human disease,
including much earlier mortality (Mourkioti et al., 2013; Sacco et al., 2010).
Unfortunately, due to the lack of the availability of this model and the challenging
nature of developing dystrophin- and telomerase-deficient mice, only mdx mice were
available for this study.

The therapeutic potential of Heregulin β-1
HRG, a trophic factor encoded by the Neuregulin-1 gene (NRG1), is one protein
of potentially fifteen splice variants (Falls, 2003; Holmes et al., 1992) (Figure 4). During
embryogenesis, HRG is necessary and involved in glial growth, cardiac development, and
acts as a neuronal cell differentiation factor (Britsch, 2007; Vartanian, Fischbach, &
Miller, 1999) . Mice that lack HRG die in utero due to cardiac defects (Barros et al., 2009;
Ueda et al., 2005). Although HRG is normally associated with neuronal tissue, HRG is
also endogenously expressed in muscle cells and vascular endothelium (Britsch, 2007).
However, mice lacking muscle-derived HRG live post partum, which confirms that HRG is
not essential for muscle development (Jaworski & Burden, 2006). Not only does HRG
have developmental roles, but HRG has positive effects on muscle function and provides
protection from cerebral and cardiac ischemic injury in adults (Britsch, 2007; Fang et al.,
2010; Zhao et al., 1998).
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Figure 4: NRG1 gene and gene products
The NRG1 gene and several potential isoforms. A) The location and genomic structure of
NRG1. B) NRG1 splice varients and resulting protein products. The 71 amino acid
fragment of HRG β-1 encoding only the EGF domain used for this study is outlined in
blue. (Adapted from Falls, 2003.)
HRG signaling via ErbB2
HRG initiates various functions through the activation of the kinase ErbB2 and its
downstream signaling (Earp, Calvo, & Sartor, 2003; Plowman et al., 1993). HRG binds to
the extracellular domain of ErbB3/ErbB4, which then heterodimerizes with ErbB2 to
initiate signaling by phosphorylation of the intracellular C-terminal domain as a result of
the heterodimeric receptor tyrosine kinase (RTK) formation between ErbB2/3 (or
ErbB2/4) (Negro, Brar, & Lee, 2004; Odiete, Hill, & Sawyer, 2012; Roskoski, 2012). When
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ErbB2/3 is activated by HRG, AKT (Protein Kinase B), and ERK 1/2 (Extracellular Receptor
Kinase / Mitogen-activated Protein Kinase) can be downstream signaling targets (Falls,
2003; Roskoski, 2012). HRG signaling is not a straight line. HRG-associated signaling
pathways and potential cellular effects are shown in Figure 5 (Newbern & Birchmeier,
2010).

Figure 5: Heregulin (NRG1) signaling pathways and cellular effects
(Newbern & Birchmeier, 2010).

HRG and neuromuscular junctions
NMJs are important for the transmission of signals from nerves to muscle and
require Acetylcholine receptor (AChR) clustering for accurate signaling (Ferraro,
Molinari, & Berghella, 2012). One of many neurotransmitters, acetylcholine (ACh), is
released from the nerve terminal to communicate instantaneously with a muscle fiber
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to orchestrate the appropriate muscle contraction (Fagerlund & Eriksson, 2009; Sudhof,
2004; Vartanian et al., 1999). When ACh is released from the motor neuron, it binds to
the AChR at a 2:1 ratio inducing the depolarization of the postsynaptic membrane and
stimulates muscle contraction (Fagerlund & Eriksson, 2009).
NMJs have a high degree of plasticity and are constantly remodeled due to
muscle contraction, making each NMJ unique (Pratt et al., 2013). Following muscle
injury, the axon branches will regenerate to reform synapses (Pratt et al., 2013). NMJs in
mdx mice are shown to be particular susceptible to damage and may contribute to
dystrophic muscle (Pratt et al., 2013). NMJs are malformed in DMD patients as well as in
mdx mice and demonstrate a discontinuous bouton formation as shown in Figure 6. In
mdx mice, axonal branching is increased and bundles of AChRs are dispersed resulting in
NMJ fragmentation (Pratt et al., 2013).
In the peripheral nervous system, Schwann cells form a necessary protective
myelin sheath that promotes faster nerve impulses and while residing at the NMJ, help
to stabilize the interaction with muscle through adherence to the basement membrane
(Corfas, Velardez, Ko, Ratner, & Peles, 2004). In a recent publication, HRG signaling
response in Schwann cells restored thickness of the myelin sheath and induced
hypermyelination of damaged nerves (Stassart et al., 2013). HRG signaling via ErbB2 is
known to regulate AchR gene transcription and other proteins in NMJs (Bezakova &
Ruegg, 2003; Handschin et al., 2007).
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Figure 6: WT and mdx NMJs
NMJs were identified by labeling AChRs with α-bungarotoxin-alexa fluor 555 and imaged
by confocal microscopy. Wild type (WT) mouse (Left) showing a continuous “pretzel –
like” NMJ formation and an mdx mouse (Right) showing a discontinuous bouton NMJ
formation distributed in islands due to the absence of the dystrophin protein.

HRG may affect NMJ formation though ERK activation. Through in vitro
experiments, HRG activated ERK in C2C12 myoblasts and myotubes resulted in the upregulation of NMJ genes which can be beneficial for NMJ formation and possibly
translate to the restoration muscle function (Handschin et al., 2007; Tansey, Chu, &
Merlie, 1996). HRG effects on NMJ formation may improve the excitation-contraction
coupling, an action potential resulting in a contraction, which is defective in DMD
patients due to poorly formed NMJs (Schertzer, van der Poel, Shavlakadze, Grounds, &
Lynch, 2008). Signaling from the HRG-ERK-NMJ gene up-regulation pathway at the NMJ
is shown in Figure 7 (Bezakova & Ruegg, 2003).
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Figure 7: HRG signaling at the NMJ
HRG is shown to regulate transcription of AChR and other NMJ genes though its
receptor kinase, ErBb2/3 (adapted from Bezakova G & Ruegg M, 2003).
Heregulin and utrophin
Heregulin β-1 (HRG) has shown therapeutic qualities in the mdx mouse as well as
an effect on utrophin levels in vitro (Basu et al., 2007; Gramolini et al., 1999; Krag et al.,
2004). Utrophin, an autosomal homolog of dystrophin, forms a similar utrophinassociated glycoprotein complex in the neuromuscular junction and has an 80%
homology to dystrophin (Marshall & Crosbie-Watson, 2013; Voisin & de la Porte, 2004).
Utrophin up-regulation is a popular therapeutic theory for the substitution of
dystrophin. Utrophin has been shown to be up-regulated by HRG in C2C12 cells and in
mdx mice (Basu et al., 2007; Handschin et al., 2007; Krag et al., 2004). It was observed
that the transgenic induction of utrophin improved the dystrophic phenotype in mdx
mice (Nowak & Davies, 2004; J. Tinsley et al., 1998). HRG-treated mice were also shown
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to have improved strength, decreased inflammation, and reduced muscle damage; this
improvement was postulated to be mediated by an increase in utrophin (Krag et al.,
2004).
One of the limitations in the Krag study was the small number of mice studied.
The mdx mouse phenotype is highly variable. Only five mice were treated and it has
been shown by Nagaraju and Wilmann that a minimum of 10 mice are needed to
significantly power an mdx therapeutic study (Nagaraju & Willmann, 2009). It was
proposed by Krag that a two-fold induction of utrophin was sufficient to ameliorate the
dystrophic phenotype. Results from experiments performed at BioMarin have shown 2fold differences in utrophin protein and mRNA levels between individual mdx mice; such
individual variation raises questions about the significance of such a small change in
utrophin levels (S. Bell, personal communication). Although no clear mechanism of
action was identified, HRG had beneficial therapeutic effects improving the dystrophicphenotype (S. Bell, personal communication).

Hypothesis
DMD is a progressive muscle wasting disease with no cure. HRG was shown to
alleviate the dystrophic phenotype in mdx mice. HRG has also been shown to activate
ERK in C2C12 myotubes inducing the gene transcription of many NMJ proteins including
the dystrophin homolog, utrophin. Although utrophin did not appear to be significantly
affected by HRG in vivo, ERK involvement in other proteins involved in NMJ function
would be of interest. AKT has been shown to be important for muscle health and fiber
type switching to promote stronger fibers and has been identified as a downstream
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target of HRG signaling. Based on these observations, it is hypothesized that HRG
activation of ERK and AKT and the activation of proteins downstream of AKT and ERK
might be responsible for NMJ gene induction, improved cell survival, or other effect that
ameliorated the dystrophic phenotype observed in HRG-treated mdx mice. Specifically,
AChR clustering and NMJ formation were of interest as they had previously been
identified as downstream targets of HRG and ERK signaling. This thesis evaluated the
effects of HRG on muscle biochemically, through cell signaling assays, and histologically,
by analysis of AChR clustering in vitro and NMJ formation in vivo, to elucidate a
mechanism of action.
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Materials and Methods:
C2C12 cell culture and myotube differentiation
C2C12 mouse myoblasts were cultured in DMEM (Dulbecco's Modified Eagle
Medium) high glucose plus GlutaMAX with 1% Pen/Strep and 10% fetal bovine serum
(normal growth medium) (all from Life Technologies) (McMahon et al., 1994). Cells were
between 2 and 10 passages before seeding into 6, 12, or 96 well cell culture treated
plates (Costar) and maintained at ≤50% confluency. To differentiate myoblasts into
myotubes, cells were grown to 80% confluency and switched to DMEM containing 2%
horse serum (Invitrogen) for at least 3 days for differentiation and then switched back to
normal growth medium.

Signaling and cell lysis
A 71 amino acid rhHRG fragment encoding only the EGF domain was obtained
from R&D Systems and resuspended in Tris-buffered saline (TBS). Cultured myoblasts or
myotubes were serum-starved for up to 4 hours and then treated with phosphatebuffered saline (PBS, vehicle) or HRG up to 1600ng/mL, washed with ice cold PBS, and
lysed by the addition of a sufficient amount of RIPA buffer (Sigma) containing
phosphatase and protease inhibitors (Pierce) at various time points. Each condition was
collected separately and centrifuged. The pellets were discarded and supernatants
reserved. All samples were then kept on ice for the duration of the experiment or stored
frozen at -80°C for later analysis.
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Total protein concentration of cell supernatants was determined by a BCA
protein Assay Kit (Pierce). Samples were diluted appropriately with RIPA buffer to
normalize protein concentrations for all samples per experiment. SDS-PAGE sample
buffer and reducing agent (NuPAGE, Life Technologies) were added to samples, boiled
and centrifuged at max speed for 30 seconds. Samples were resolved by SDS-PAGE on 412% Bis-Tris NuPAGE gels (Invitrogen). Gels were transferred to nitrocellulose
membranes with an iBlot (Invitrogen) and blocked for 45 minutes at room temperature
with StartBlock (Pierce). Membranes were probed overnight at 4°C with primary
antibodies, washed, and probed with fluorescent- or HRP-conjugated secondary
antibodies for 45 minutes. The blots were processed and images acquired on a
Fluorchem M Imager (Protein Simple). Images were analyzed by band densitometry
(Alpha View SA).

Antibodies
All antibodies used for Western blotting were purchased from Cell Signaling; ERK
1/2: mouse L34F12, Phospho-ERK: rabbit Y204, AKT: mouse 4074, Phospho-AKt: rabbit
S473. Secondary antibodies were purchased from Invitrogen: goat anti-mouse alexa
fluor 546, goat anti-rabbit alexa fluor 430, anti-mouse HRP conjugate, anti-rabbit HRP
conjugate.

Electrochemiluminescence (ECL) /MSD (Meso Scale Discovery) detection
Differentiated C2C12 myotubes were HRG-treated or vehicle-treated, washed
with ice-cold PBS, and lysed and normalized as described above. Cell supernatants were
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assayed using a Meso Scale Discovery electrochemiluminescence (ECL) assay as per the
manufacturer’s instructions for AKT, ERK1/2, GSK3-β, JNK, p-38, and mTOR1/2.

Histology and cell staining
C2C12 cell culture followed the same protocol as mentioned previously with the
following exception, cells were either plated into fibronectin coated (25µg/mL,
Invitrogen) 4-well chamber slides (glass or plastic) or 96-well UV-transmissible plates
(Greiner, cell culture treated). 20, 40, or 60µM Laminin-111 (laminin) (Sigma) was added
on day 3 of differentiation, at the same time 8ng/mL or 80ng/mL HRG was administered
for 48-72 hours. Once the HRG-treatment time course was finished, cells were
incubated with alpha-bungarotoxin (α-btx) conjugated to alexa fluor 555, (5µg/mL,
Invitrogen) for 1 hour at 37°C, washed with PBS and fixed with 4% paraformaldeyde for
30 minutes at room temperature or cold methanol for 10 minutes on ice. The cells were
then washed with PBS and permeabilized with 0.02% Triton X-100 (Sigma) with Hoechst
to visualize nuclei (Life Technologies). Chamberslides were washed, dried overnight, and
mounted with Prolong Gold Antifade with DAPI and 96-well plates were washed,
incubated with Hoechst and left in 150µL of PBS at 4°C until imaged.

Fluorescent microscopy
Chamberslides were imaged on a Leica DM4000b fluorescent microscope fitted
with a DFC 550 CCD camera with 20x and 40x objectives and analyzed with LAS AF
software. Whole chamberslide images were acquired and stitched together using an
Image Express and MetaMorph Software (Molecular Devices). 96-well plates were
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imaged on an Image Express and processed using Columbus Software (Perkin Elmer) by
batch analysis of 16 fields per well n≥3 wells per condition. AChR cluster count, cluster
area determination and intensity were calculated by determining a minimum threshold
of 70% and identifying clusters through spot detection with area >300nm² and
<6000nm² and corrected spot intensity >450 and contrast >0.3 similar to Ball, et al.
(Matthew K. Ball, 2013). Statistical analysis of variance was performed using the
Students T-test (one-tailed, two sample of unequal variance).

In-vivo HRG efficacy study
Three week old mdx and WT 10snJ mice were treated three times a week with
vehicle (PBS) or 200µg/kg of HRG via intraperitoneal injection: 10 WT + vehicle, 12 mdx
+ vehicle, and 13 mdx + 200ug/kg HRG. An effort to exacerbate the mild mdx pathology
was attempted by submitting the mice to 30 minute treadmill exercise twice a week.
The study continued for 3 months and mice were sacrificed and tissues harvested for
functional or histological analysis. A time course of HRG-treatments during the animal
study is shown in Figure 8.
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Figure 8: Time course of HRG-treatment in mice
tissue sectioning and immunohistochemistry
Fresh frozen tibialis anterior muscles (TA) from the HRG efficacy study were
warmed to -20°C overnight. Tissues were placed in a cryostat (LEICA CM 1950) for 20
minutes to equilibrate temperature. Several 35µm thick longitudinal sections were
transferred onto positively charged slides per condition. Tissues were fixed in 4%
paraformaldehyde for 30 minutes followed by three washes with PBS for 5 minutes
each. Tissues were subjected to 0.3M glycine to reduce autofluoresence, blocked and
permeabilized for 45 minutes with 0.02% Triton X-100 and 0.5% BSA (Sigma), and
followed by a series of washes with PBS (Life Technologies). Tissues were stained
overnight with primary anti-neurofilament (NF) antibody (Developmental Studies
Hybridoma Bank – University of Iowa) at 4°C. Slides were washed and then incubated
with alexa fluor 488-conjugated secondary antibody (Life Techniologies) and alexa fluor
555-conjugated α-btx (5µg/mL, Invitrogen) for 45 minutes at room temperature in
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blocking buffer. The samples were dried overnight and mounted with Prolong Gold
Antifade with DAPI (Invitrogen).

Epi-fluorescence and confocal microscopy of tissue sections
Sections were initially imaged & analyzed with a Nikon E800 Upright Epifluorescent microscope. Around 48 NMJs were imaged per mouse (n=7) for each
condition through fluorescent microscopy. Confocal images were captured with a 40x oil
objective and 20-24 Z-stacks, each stack ~1-1.7µm on a Carl Zeiss LSM780 confocal
microscope. Around 6 NMJs per mouse (n=4) for each condition were imaged and
analyzed by confocal microscopy. Confocal raw data images were extracted with Imaris
software and processed using Image J software.
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Results:
HRG signaling in myoblasts and myotubes
The effect of HRG to ameliorate the dystrophic phenotype in mdx mice through
the up-regulation of utrophin has not been consistently shown as an HRG mechanism of
action (Krag et al. 2004 & S. Bell, personal communication). To help identify the
mechanism of action by which HRG preserves muscle function, HRG signaling was
investigated. It had previously been shown that HRG activates ERK in skeletal muscle
and induces gene expression of NMJ proteins (Altiok, Altiok, & Changeux, 1997; Fromm
& Burden, 2001; Handschin et al., 2007; Tansey et al., 1996). To confirm previous
findings and to establish experimental protocols, ERK activation by HRG was examined.
Mouse C2C12 myoblasts and differentiated myotubes were serum-starved and
then treated with varying concentrations of HRG for various times. Activated signaling
proteins were analyzed by Western blot with phospho-specific antibodies. Activation
was normalized by the ratio of phosphorylated to non-phosphorylated protein signal.
HRG activation of ERK in undifferentiated myoblasts is shown in Figure 9. HRG activation
of ERK in differentiated myotubes showed a dose dependent response (Figure 10 & 11).
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Figure 9: Activation of ERK in undifferentiated myoblasts
Western blot and densitometry analysis at 10 minutes showing ERK activation with 200 and
800ng/mL HRG in undifferentiated myoblasts. Each condition was performed in duplicate. These
data are representative of 3 experiments.
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Figure 10: HRG activation of ERK in differentiated myotubes
Differentiated myotubes were treated with 0, 50, 100, 400, 800 & 1600ng/mL HRG for
15 minutes. Lysates were analyzed by Western blot and densitometry analysis. Each
condition was performed in duplicate. These data are representative of 3 experiments.

The HRG-mediated activation of ERK confirmed previous findings of ERK
activation in C2C12 cells. Since ERK activation occurred in undifferentiated myoblasts
and differentiated myotubes, a direct effect, specific to differentiated muscle myotubes,
could not be linked to ERK activation following HRG treatment. Other MAP Kinase
pathways, JNK (c-Jun N-terminal kinase) and p38 were examined. JNK and p38 are
crucial for cell survival and regulate cell proliferation (Bernet et al., 2014; Sakamoto &
Goodyear, 2002). In order to simplify the MAP Kinase pathway analysis into a single
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experiment, ERK, JNK and p38 protein and their phospho-protein isoforms were assayed
in a single ECLA experiment (n=2 biological replicates per experiment, n=6 experimental
replicates). The results confirmed a HRG dose dependent activation of ERK, peaking at
10 minutes (Figure 11), but revealed no activation of JNK (Figure 12) or p38 (Figure 13)
in differentiated C2C12 myotubes..

Figure 11: HRG dose dependent ERK activation
ECLA showing that HRG activation of ERK peaks by 10 minutes at 40 and 200ng/mL HRG.
Data are the average of duplicates and representative of 6 independent experiments.

Figure 12: HRG does not activate JNK
ECLA showing that HRG does not appear to activate JNK between 5 and 30 minutes at 8,
40, or 200ng/mL HRG. Data are the average of duplicates and representative of 6
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independent experiments.

Figure 13: HRG does not activate p38
ECLA showing that HRG does not appear to activate p38 between 5 and 30 minutes at 8,
40, or 200ng/mL HRG. Data are the average of duplicates and representative of 6
independent experiments.

AKT has been shown to be important in muscle, and HRG activation of AKT has
previously been demonstrated in non-muscle cells in vitro. However, it is not clear if
HRG activation of AKT in dystrophic muscle would be beneficial. AKT is linked to muscle
cell survival, differentiation through the stimulation of growth factors, fiber type
switching, and glucose metabolism (Blaauw et al., 2009; Blaauw et al., 2008; Schiaffino
& Mammucari, 2011). To test the activation of AKT in muscle-derived cells, C2C12
myoblasts and myotubes were treated with HRG as in the MAP kinase experiments
above. Dose-dependent activation of AKT was detected following HRG-treatment.
However, unlike ERK, AKT was only activated in differentiated myotubes (Figure 15) and
not myoblasts (Figure 14). This myotube specific effect could mean that downstream
events from AKT activation might contribute to the prevention of muscle dystrophy
(Bodine et al., 2001).
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Figure 14: Activation of AKT in undifferentiated C2C12 myoblasts
Myoblasts were treated with 0, 50, 100, 400, 800 & 1600ng/mL HRG for 10 minutes.
Lysates were analyzed by Western blot and densitometry analysis. Each condition was
performed in duplicate. These data are representative of 3 experiments.

Figure 15: Activation of AKT in differentiated C2C12 myotubes
Differentiated myotubes were treated with 0, 50, 100, 400, 800 & 1600ng/mL HRG for
10 minutes. Lysates were analyzed by Western blot and densitometry analysis. Each
condition was performed in duplicate. These data are representative of 3 experiments.
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As AKT activation was differentially activated in C2C12 myotubes, downstream
signaling might be important for potential AKT-mediated benefits. Downstream
pathways of AKT were investigated to explore HRG signaling. GSK-3β, a substrate of AKT,
was investigated because of its involvement in cell fate, development, and glycogen
synthesis (Wojtaszewski, Nielsen, Kiens, & Richter, 2001). It was previously shown that
the activation of p70s6k from AKT was linked to the alleviation of muscular dystrophy by
promoting muscle cell survival (Boppart, Burkin, & Kaufman, 2011). In order to simplify
analysis of downstream AKT signaling, AKT, GSK-3β and p70s6K protein and phosphoprotein isoforms were assayed in a single ECLA experiment (n=2 biological replicates per
experiment, n=6 experimental replicates). While these experiments confirmed
activation of AKT between 5 and 30 minutes (Figure 16), it was observed that HRG did
not activate either GSK-3β (Figure 17) or p70s6K (Figure 18) up to 90 minutes following
HRG treatment (data not shown). Although the GSK-3β data at 5 and 10 minutes
suggested there might have been activation, in six additional experiments, this
observation was never repeated.

Figure 16: HRG dose activation of AKT in C2C12 myotubes
ECLA showing that HRG activation of AKT peaks by 5 minutes at 8, 40, and 200ng/mL
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HRG, but remains active for at least 30 minutes. Data are the average of duplicates and
representative of 6 independent experiments.

Figure 17: HRG does not activate GSK-3β
ECLA showing that HRG does not appear to activate GSK-3β between 5 and 90 minutes
at 8, 40, or 200ng/mL HRG. Data are the average of duplicates and representative of 6
independent experiments.

Figure 18: HRG does not activate p-70s6k
ECLA showing that HRG does not appear to activate p70s6k between 5 and 30 minutes
at 8, 40, or 200ng/mL HRG. Data are the average of duplicates and representative of 6
independent experiments.
mTOR, another protein downstream of AKT and linked to the prevention of
muscle atrophy and mitochondrial health, was investigated (Bodine et al., 2001). mTOR
showed no activation following HRG treatments up to 90 minutes in an ECLA (Figure 19),
which was confirmed by Western blot analysis (data not shown). The results were
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unexpected as mTOR is responsible for cell survival and is a common target of AKT
signaling (Bodine et al., 2001). It is important to keep in mind that the signaling
experiments were performed in C2C12 myotubes in vitro, not muscle tissue in vivo. The
C2C12 myotubes may be an incomplete model for signaling in muscle.

Figure 19: HRG does not activate mTOR
ECLA showing that HRG does not appear to activate mTOR between 10 and 90 minutes
at 8, 40, or 200ng/mL HRG. Data are the average of duplicates and representative of 6
independent experiments.

HRG effects on AChR clusters in C2C12 myotubes
The activation of ERK by HRG has been shown to induce the expression of
several NMJ proteins including AChR (Handschin et al., 2007). It has also been shown
that laminin induces AChR clustering in differentiated C2C12 myotubes, and dystrophindeficiency contributes to the loss of AChR cluster organization (Personius & Sawyer,
2005; Sugiyama, Glass, Yancopoulos, & Hall, 1997). The effects of HRG signaling on
laminin-induced AChR clustering and morphology in differentiated C2C12 myotubes
were examined by histological analysis. AChR clustering occurred spontaneously in
differentiated myotubes (Figure 20A). The addition of laminin induced or accelerated
AChR clustering in C2C12 cells plated on fibronectin-coated slides (Figure 20B), while
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HRG-treatment reduced AChR clustering (Figure 20C). C2C12 myotubes, which were
treated with HRG and laminin at the same time, appeared to show an effect on the
spatial organization of AChR clusters. It was observed that HRG appeared to influence
the location of laminin-induced AChR clusters with some clusters having a central
localization (Figure 20D) compared to only being on an edge, whether a cell-cell or cellmatrix interaction (Figure 20B). This phenomenon indicated HRG-treated Laminin
induced AChR clusters might be more matrix-cell independent. In HRG-treated
myotubes, the α-btx stain appeared dimmer in laminin-induced clusters (Figure 20D)
while having a brighter and more diffuse membrane staining in the absence of laminin
(Figure 20C), suggesting a greater dispersal of AChRs. These results are similar to
observations in the scientific literature (Trinidad & Cohen, 2004).
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Figure 20: HRG modulated AChR clustering in differentiated C2C12 myotubes
Epi-fluorescence microscopy of a-btx stained C2C12 differentiated myotubes on
fibronectin-coated slides. No Laminin-1 or HRG added (A), 60nM Laminin-1 (B), 8ng/mL
HRG induction (C) (D) 60nM Laminin-1 and 8ng/mL HRG induction (D). Note: Blue arrows
represent AChR clustering, white arrors shows AChRs dispersed throughout myotubes
or centralized cluster.
To quantitate the observations made subjectively on AChR clustering in C2C12
myotubes plated on fibronectin-coated slides, C2C12 cells were plated onto 96 well UVtransmissable plates for high content analysis. The following conditions were tested at
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24, 48, 72 and 96 hours with the number of wells indicated (n): No laminin+no HRG
(n=12); no laminin+8ng/mL HRG (n=6); no laminin+80ng/mL HRG (n=6); 20nM
laminin+no HRG (n=6); 40nM laminin+no HRG (n=6); 60nM laminin+no HRG (n=6); 20nM
laminin+8ng/mL HRG (n=3); 40nM laminin+8ng/mL HRG (n=3); 60nM laminin+8ng/mL
HRG (n=3); 20nM laminin+80ng/mL HRG (n=3); 40nM laminin+80ng/mL HRG (n=3);
60nM laminin+80ng/mL HRG (n=3). Sixteen fields from each well were imaged by an
Image Express (Molecular Devices) for a minimum of 48 images per condition. Each field
contained 2-12 myotubes or fractions of myotubes. The images were analyzed in batch
using Columbus software (Perkin Elmer) to identify clusters as detailed in Materials and
Methods. AChR clusters were identified, counted, and the cluster area and intensity
determined. The intensity value is relative to the concentration of AChRs found in
clusters while the area is indicative of cluster size. At 24 hours following HRGtreatments, there was no significant difference in the trending of AChR clustering (data
not shown). However, HRG had a dose-dependent effect on the laminin-induced AChR
clusters on cluster number, total cluster intensity (Figure 21A) and mean cluster area
(Figure 21B) at 48 hours. The addition of 80ng/mL HRG reduced the total number of
20nM and 60nM laminin-induced clusters/well by 34% (p<0.02) and 23% (p=0.05),
respectively. While HRG treatment reduced the total cluster intensity of laminin-induced
clusters, only at 80ng/mL HRG and 60nM laminin-1 was the effect statistically significant
(p<0.01). Similarly, HRG significantly reduced the mean cluster size (area) at 80ng/mL
for the 60nM laminin-induced clusters (p<0.01). AChR clustering was also examined at
72 hours (Figure 22) and, similar to the observations made at 24 hours, no trend was
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observed. The dose-dependent HRG-effects appeared to diminish by 72 hours. No
attempt was made to determine localization of AChR clusters as that appeared to be
beyond the capacity of the algorithm for the staining protocol that was performed.

Figure 21: AChR clustering after a 48 hour HRG treatment
AChR clustering count in differentiated C2C12 myotubes on the fifth day of
differentiation with a 48 hour HRG treatment of 8 and 80ng/mL HRG on spontaneous
and laminin-induced AChR cluster formation showing (A) sum cluster intensity/well and
(B) area/AChR cluster. Error bars depict standard deviation of well averages.

36

Figure 22: AChR clustering after a 72 hour HRG treatment
AChR clustering count in differentiated C2C12 myotubes on the sixth day of
differentiation with a 72 hour HRG treatment of 8 and 80ng/mL HRG showing (A) sum
cluster intensity/well and (B) area/AChr cluster. Error bars depict standard deviation of
well averages.
Effects of HRG on NMJ formation in vivo
Our observation of HRG activation of ERK, its documented downstream effects
on NMJ gene transcription, and our observation of AChR cluster reorganization led us to
examine whether HRG might affect NMJ morphology in the mdx mouse. NMJs, which
are shown to be defective in mdx mice (Figure 6), might benefit from ERK and/or AKT
signaling. In order to understand the effect HRG has on NMJ formation, the TA muscles
from vehicle and HRG-treated mdx mice and vehicle-treated wild type (WT) mice were
examined by staining with alexa fluor 555-conjugated α-btx, which stains the AChR on
the muscle side of the NMJ. Figure 23 shows WT, mdx and HRG-treated mdx NMJs. The
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vast majority of the WT NMJs examined in this study were comparable to those found in
the scientific literature showing a continuous pretzel-like NMJ (Figure 22A and 23A)
(Arnold et al., 2014; Bolliger et al., 2010). The mdx mouse had discontinuous NMJ
formation, which is commonly referred to in the literature as Island-like or bouton
formation. The NMJ islands in HRG-treated mdx tissue appear to be more conjoined
(Figure 23C and 24) when compared to the random, bouton mdx NMJs (Figure 23B and
24). HRG treatment did not completely restore the mdx NMJ phenotype to WT, but HRG
treatment did show a partial restoration of NMJ morphology.

Figure 23: General NMJ morphology
WT 10snJ mice show healthy pretzel-like NMJs (A) while mdx mice show a
discontinuous, island-like NMJs (B), and 200ug/kg HRG-treated mdx mice show a
partially restored morphology (C).

To further understand any effects HRG might have beyond changes in overall
NMJ morphology, the interaction between the nerve terminal and muscle were
analyzed by co-staining with an antibody to neurofilament (NF) protein found in the
axon termini and alexa fluor 555-conjugated α-btx to label AChRs on the muscle fiber.
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Through Epi-fluorescence microscopy, it was observed that in some NMJs the axons of
nerve terminals had higher integration throughout the NMJ when mdx mice were
treated with HRG than compared to the vehicle-treated mdx mice (data not shown) and
was confirmed through confocal microscopy (Figure 24A). Confocal microscopy was
used to determine a more precise location of axonal and AChR interactions. HRGtreated tissues showed a higher nerve terminal integration with AChR throughout the
NMJ, as though the nerve was trying to compensate for the NMJ malformation by
reaching out to each island when compared to the vehicle-treated mdx mouse muscle,
where nerve terminal integration appeared very inconsistent.
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Figure 24: HRG effects on AChR and axonal interactions
NMJs are shown in red and the axon (nerve terminal) is shown in green. Confocal
microscopy showing location of axonal and NMJ interaction in WT (Left), mdx + vehicle
(middle), and 200µg/kg HRG-treated (Right) NMJs. HRG effects on AChR and axonal
interactions showing increased integration (A), however, HRG effects on NMJ and
axonal interactions are not consistent (B). Data are representative of 6 NMJs analyzed
per mouse, 4 mice per condition.

40

It appeared that HRG-treated mice showed a higher integration of nerve
terminals throughout the NMJ compared to the vehicle. Yet, the effect seen from HRGtreatments was not consistent among all NMJs (24B), possibly due to incomplete
biodistribution of HRG. This data led us to the possible conclusion that HRG might
modify NMJ formation and possibly influence nerve terminal migration to better adapt
to signaling in mdx NMJs and improve muscle function through increased excitation
contraction coupling.

Results summary
In summary, through in vitro and in vivo experiments, mechanisms of action for
HRG-mediated effects on muscle were examined. HRG signaling in vitro provided
confirmation of ERK activation in undifferentiated myoblasts and differentiated
myotubes, whereas AKT activation was observed only in differentiated myotubes. There
was no clear evidence of JNK, p38, GSK-3β, p70s6K or mTOR activation. Due to HRG
activation of ERK and NMJ gene up-regulation as a result of ERK signaling, AChR
clustering in differentiated C2C12 myotubes was investigated and found to have a dosedependent decrease in AChR cluster area and intensity. NMJ morphology was examined
in vivo following the administration of HRG to mdx mice. NMJs in mdx mice treated with
HRG showed a partial restoration in NMJ morphology. Co-staining AChRs of HRG-treated
and non-treated mdx mice with a NF antibody provided evidence that HRG increased
NMJ integration between the nerve terminal and AChRs, which could lead to improved
excitation contraction coupling resulting in improved muscle function.
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Discussion:
A downstream signaling mechanism has not yet been determined
The HRG signaling pathway in muscle has not been completely elucidated. In
differentiated C2C12 myotubes, HRG activates AKT and ERK, but surprisingly does not
activate mTOR, JNK, p-38, p70s6k, or GSK-3β, which are downstream of AKT and ERK or
represent parallel pathways. Downstream signaling of ERK in C2C12 myoblasts and
myotubes have been thoroughly studied and, for the most part, point to the induction
of AChR, utrophin and many other NMJ-associated genes. The results presented here
indicate that the ERK activation observed in C2C12 cells may translate to the
reorganization of laminin-induced AChR clusters in vitro and the improvement of NMJ
formation in vivo. Although the result could be predicted based on literature, this study
is the first to make the direct observation of HRG affecting the NMJ of mdx mice in vivo.
Although AKT is activated in vitro in C2C12 myotubes, the effects of this activation were
not determined in this study.
HRG activation of AKT did not lead to the activation of GSK-3β, mTOR, or
p70s6k, downstream mediators of AKT signaling. This result was surprising and indicates
that there may be a separate pathway activated by HRG through AKT. More likely, it
could mean that C2C12 cells are not a surrogate for muscle when examining AKT
signaling. AKT signaling is responsible for fiber-type switching, muscle fiber hypertrophy
and decreased muscle apoptosis. However, it was not possible to examine these effects
in vitro. These responses to AKT activation could be mediated by mTOR, which is
responsible for cell survival and has been shown to prevent muscle atrophy in vivo, so it
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was surprising to find HRG did not activate mTOR (Bodine et al., 2001). HRG activation
of AKT was specific to myotubes and might point to a different outcome for more
mature muscle upon the administration of HRG. Due to the limitations in the C2C12 cell
culture model, investigation of AKT and mTOR signaling in vivo may yield different
results.

HRG decreases AChR clustering in C2C12 differentiated myotubes
ERK activation has been associated with NMJ-associated gene expression. As
HRG activated ERK, it might be expected that an effect on AChR clusters would be
observed. What was surprising was the nature of the HRG effects. One would expect
that HRG-treatments might increase AChR clusters as HRG treatment has been shown to
increase total AChR protein. What was observed in this study, however, was not an
increase in AChR clusters, but a decrease in number, area, and intensity of the Laminininduced AChR clusters at 48 hours. There was an increase in overall clusters in the 72
hour time point compared to the 48 hour time point. However, the HRG effects seemed
to diminish by 72 hours. Interestingly, there did not seem to be a trend in AChR clusters
treated with only laminin.

When myotubes were not subjected to HRG or laminin treatments, AChR
clustering is spontaneous as shown in Figure 20A. AChRs in myotubes treated with HRG
(Figure 20C) appeared to be more dispersed throughout the membrane when compared
to treatment of cells with Laminin-1 (Figure 20B). Further investigation could focus on
whether the HRG-treated AChR cluster migration (differences in spatial orientation
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throughout the myotubes when compared to just the Laminin-1 treatment) observed in
cell culture translates to the partial repair in NMJs as seen in vivo (Figure 23 and 24).

HRG modifies NMJ morphology to improve axonal integration
It was observed that AChR clusters not only decrease in the presence of HRG, but
clusters were not restricted to the edges of myotubes suggesting enhanced remodeling,
dispersion, and/or plasticity resulting from HRG signaling; this finding led to the
investigation of HRG-effects on NMJ formation. HRG partially repaired NMJ morphology,
reducing the bouton formation and increasing contiguous α-btx staining. It is unclear
whether this observation is a direct result of ERK activation, but many studies have
indicated a role for ERK activation by HRG in the control of NMJ gene regulation and
would support an effect mediated through ERK. It would be interesting to evaluate
correlations between ERK activation and partial repair of NMJ following HRGtreatments. Although HRG may appear to modify NMJ formation and increase axonal
and NMJ integration, these observations are not consistent between all NMJs or mice.
As some mice responded better to HRG treatments (S. Bell, personal communication),
this could be due to the variability of the mdx model, bioavailability of HRG to all muscle
tissue or a combination of both factors. Further analysis by BioMarin of other tissues
could help resolve these issues.
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Conclusion:
It has been observed that HRG can ameliorate the dystrophic phenotype in mdx
mice. However, the mechanism of action of HRG had not been identified. In fact the
proposed mechanism of utrophin induction was not reproduced by BioMarin
researchers.

The goal of this thesis was to explore and/or determine alternative

mechanisms of action that would explain the benefits of HRG treatment on dystrophic
muscle. Although AKT activation in C2C12 cells possibly created more questions than
were answered, the reproducible activation of ERK and the body of literature linking ERK
to the regulation of NMJ genes supported the examination of HRG effects on AChR
clustering and NMJ formation. It had previously been observed that AChR total protein
increases upon HRG treatment. However, an increase in AChR clusters was not
observed. Just the opposite was observed: fewer clusters, less area per cluster and at a
lower intensity indicating fewer AChR/cluster. Another observation was that AChR
clusters were not restricted to the edges of tubes, suggesting enhanced remodeling or
plasticity was induced by HRG treatment. When NMJs were analyzed in TA muscle from
HRG-treated mdx mice, an improvement in NMJ morphology and neurofilament
interaction was observed, supporting a potential role of HRG in promoting NMJ
plasticity and repair of defective mdx NMJ. This improved NMJ structure may improve
excitation contraction coupling to restore muscle function or prevent muscle damage.
Although not definitive, this thesis goes a long way towards suggesting a novel
mechanism of action for HRG in the amelioration of the dystrophic phenotype
associated with dystrophin deficiency through the repair of NMJ and/or restoration of
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NMJ function. The evidence reported here supports a role for HRG involvement in NMJ
plasticity and repair to improve excitation contraction coupling in mdx mice as a
possible mechanism of action to preserve muscle function in a DMD animal model.
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